Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_2
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

completed267%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_2

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

NCT04438096
completedphase_2

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

NCT00918749
completedphase_3

Flibanserin Versus Placebo in Premenopausal Women With HSDD

NCT00491829

Clinical Trials (3)

Showing 3 of 3 trials
NCT04438096Phase 2

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Unknown
NCT00918749Phase 2

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Completed
NCT00491829Phase 3

Flibanserin Versus Placebo in Premenopausal Women With HSDD

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3